Targeting renal cell carcinoma with a HIF-2 antagonist.
Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, Homayoun F, Ma Y, Patel N, Yell P, Hao G, Yousuf Q, Joyce A, Pedrosa I, Geiger H, Zhang H, Chang J, Gardner KH, Bruick RK, Reeves C, Hwang TH, Courtney K, Frenkel E, Sun X, Zojwalla N, Wong T, Rizzi JP, Wallace EM, Josey JA, Xie Y, Xie XJ, Kapur P, McKay RM, Brugarolas J.
Nature. 2016 Nov 3;539(7627):112-117. doi: 10.1038/nature19796. Epub 2016 Sep 5.
Investigating erythropoietin resistance.
Koury MJ.
N Engl J Med. 1993 Jan 21;328(3):205-6. doi: 10.1056/NEJM199301213280309.
Resistance to erythropoietin.
Lacombe C.
N Engl J Med. 1996 Mar 7;334(10):660-2. doi: 10.1056/NEJM199603073341012.
[Erythropoietin resistance].
Branger B.
Nephrologie. 2002;23(1):3-5.
Erythropoietin and resistant hypertension in CKD.
Boyle SM, Berns JS.
Semin Nephrol. 2014;34(5):540-9. doi: 10.1016/j.semnephrol.2014.08.008.
Inflammation, serum C-reactive protein, and erythropoietin resistance.
Bárány P.
Nephrol Dial Transplant. 2001 Feb;16(2):224-7. doi: 10.1093/ndt/16.2.224.
Erythropoietin response to anaemia in heart failure.
Montero D, Haider T, Flammer AJ.
Eur J Prev Cardiol. 2019 Jan;26(1):7-17. doi: 10.1177/2047487318790823. Epub 2018 Aug 2.
Erythropoietin-induced hypertension.
Ismail N, Ikizler TA.
J Med Liban. 1997;45(1):25-30.
Poor response to erythropoietin.
Macdougall IC.
BMJ. 1995 Jun 3;310(6992):1424-5. doi: 10.1136/bmj.310.6992.1424.
[Erythropoietin-induced hypertension].
Ioka T, Kusano E.
Nihon Rinsho. 2006 Sep 28;Suppl 3:513-6.
